Cullinan Oncology Inc — Stato Patrimoniale (NASDAQ:CGEM) | MetaTrader

Apri il grafico completo

Financials

Panoramica Estratto Conto Statistiche

Trimestrale Annuale

Totale attivo 437.19 M561.12 M484.18 M621.82 M448.37 M Totale passività 11.81 M26.09 M30.29 M31.5 M39.64 M Patrimonio netto totale 425.37 M535.03 M453.89 M590.33 M408.73 M Totale passività e patrimonio netto 437.19 M561.12 M484.18 M621.82 M448.37 M Debito totale ——5.59 M2.15 M— Indebitamento netto ——-461.48 M-396.85 M—

Notizie

Clear Street conferma il rating su Cullinan Oncology dopo l’accordo Gilead

Stifel alza il target su Cullinan Oncology per progressi autoimmuni

Stifel raises Cullinan Oncology stock price target on autoimmune progress

Cullinan Therapeutics: Thesis Strengthening For T-Cell Engager Specialist (NASDAQ:CGEM)

Cullinan Therapeutics, Inc. (CGEM) Presents at Citi's 2026 Virtual Oncology Leadership Summit Transcript

TheStreet Pro Analysts Say, “Big Tech Names are Anything But Cheap – Buy These 2 Stocks Instead” - TipRanks.com

Guggenheim avvia la copertura di Cullinan Oncology con rating Buy e target di $30

Guggenheim initiates Cullinan Oncology stock with Buy rating, $30 target

Cullinan Therapeutics Stock: Cash-Rich Biotech With Multiple Value Drivers (NASDAQ:CGEM)

Are Medical Stocks Lagging AIM ImmunoTech (AIM) This Year?

Here's What Could Help Cullinan Therapeutics (CGEM) Maintain Its Recent Price Strength

Cullinan Therapeutics pianifica la pubblicazione di dati per programmi chiave autoimmuni